[1] |
KOU Jiejian, WANG Yangai.
One Case of Thrombocytopenia and Leukopenia Induced by Teicolanin and Rebabapide
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 227-230.
|
[2] |
YIN Chunyan, KONG Wenqiang, YANG Kun.
One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1181-1183.
|
[3] |
ZHANG Kaihua, LIU Dingwei, FU Changhai, SUN Xuelin, MIN Xianjun.
Effects of rosastatin combined with Danggui Buxue Tang on expressions of AR and NR3C2
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 871-877.
|
[4] |
ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang.
Detection and analysis of signals of adverse events induced by deferasirox based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
|
[5] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, NIE Xiaolu, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[6] |
LI Yaolei, WANG Zhao, LI Hailiang, ZAN Ke, JIN Hongyu, MA Shuangcheng.
Heavy metal residual and related elemental species in Polygonum cillinerve (Nakai) Ohwl
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1234-1237.
|
[7] |
LUO Yaqin, CAI Qiang, HUANG Wei.
Therapeutic effect and anti-inflammatory mechanism of Qihuang Yiqi Shexue Formula in ITP model mice
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1073-1077.
|
[8] |
XIANG Yunxia, PU Wen, LI Dongfeng, WANG Jie.
Effects of pharmacists' intervention on anticoagulant management of patients treated with warfarin after heart valve replacement
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 545-549.
|
[9] |
HUANG Wei, LUO Yaqin, WANG Xiao.
The Mechanism of Bazhen Decoction in Treating Immune Thrombocytopenia Based on Network Pharmacology
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 930-935.
|
[10] |
ZHANG Tingyu, GE Ziruo, QIAN Fang, SONG Meihua, LI Xingang, TIAN Di, XU Yanli, CHEN Zhihai, ZHANG Wei.
Clinical Effect of Continuous High-dose Convalescent Plasma Therapy for Rapidly Progressing COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 801-805.
|
[11] |
CHANG Bingqing, GUO Yixian, ZHAO Hong, LAN Xiaoxi, SU Li, SUN Wanling.
Adverse Reactions of Ultra-low Dose Decitabine in Elderly Patients with Intermediate- to high- risk Myelodysplastic Syndromes
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 776-779.
|
[12] |
LI Yu, FAN Huihui, FENG Xiaojun, WANG Yunhong, CHEN Chuantao, ZHANG Lei.
Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 939-942.
|
[13] |
CHEN Li-xiu.
Clinical Efficacy and Safety of Low Molecular Weight Heparin Combined with Warfarin in Anticoagulant Treatment of Acute Submassive Pulmonary Embolism
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(11): 651-654.
|
[14] |
ZHANG Ya-tong, FU Chun-yi, LI Zheng, DONG Fan, HU Xin.
Anticoagulation Effect and Association Analysis in Patients on Routine Warfarin Dosage
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 567-569.
|
[15] |
.
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 570-570.
|